Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis
A Phase I Study of ExoFlo, an Ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product, for the Treatment of Medically Refractory Ulcerative Colitis
Sponsor: Direct Biologics, LLC
Terminated
Enrollment challenges.
Other terminated trials from Direct Biologics, LLC
More terminations from Direct Biologics, LLC
Other Inflammatory Bowel Diseases trials with similar outcome
A PHASE1 clinical study on Inflammatory Bowel Diseases and Ulcerative Colitis, this trial is terminated or withdrawn. The trial is conducted by Direct Biologics, LLC and has accumulated 15 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
15 versions recorded-
Mar 2025 — Present [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Sep 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE1
▶ Show 10 earlier versions
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE1
-
Oct 2023 — Feb 2024 [monthly]
Recruiting PHASE1
-
Jul 2023 — Oct 2023 [monthly]
Recruiting PHASE1
-
May 2023 — Jul 2023 [monthly]
Recruiting PHASE1
-
Mar 2023 — May 2023 [monthly]
Recruiting PHASE1
-
Jan 2023 — Mar 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2022 — Jan 2023 [monthly]
Not Yet Recruiting PHASE1
-
Apr 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE1
-
Feb 2022 — Apr 2022 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2022 — Feb 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Direct Biologics, LLC
For direct contact, visit the study record on ClinicalTrials.gov .